A phase 2 trial indicates that dazukibart, a monoclonal antibody targeting interferon beta, effectively reduces disease activity in adults with dermatomyositis, especially those with skin-predominant symptoms.
A recent phase 2 trial has demonstrated promising results for dazukibart, a monoclonal antibody targeting interferon beta, in the treatment of dermatomyositis. The study, conducted across five countries, involved 75 adults with either skin-predominant or muscle-predominant dermatomyositis. Patients were randomly assigned to receive either 600 mg or 150 mg of dazukibart or a placebo.
The primary outcome measure was the change in the Cutaneous Dermatomyositis Disease Area and Severity Index-Activity (CDASI-A) score from baseline to week 12. Dazukibart 600 mg demonstrated a significant reduction in the CDASI-A score at week 12 compared to placebo in the skin-predominant cohort. While the 600 mg dazukibart group also showed numerically higher improvements in muscle-related symptoms, this difference was not statistically significant.Treatment-emergent adverse events were mostly mild and occurred in a similar proportion across all treatment groups. The authors concluded that dazukibart offers a potential new treatment option for dermatomyositis, particularly for patients with skin-predominant disease. However, they acknowledged limitations of the study, including a small sample size, lack of gender-stratified data, and limited power to detect differences in efficacy for the muscle-predominant cohort. The study was funded by Pfizer, and some authors reported financial relationships with pharmaceutical companies
DERMATOMYOSITIS MONOCLONAL ANTIBODY DAZUKIBART INTERFERON BETA CLINICAL TRIAL
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Cholesterol Gene Linked to Breast Cancer Spread, Antibody Shows PromiseA gene associated with cholesterol levels may also influence the spread of breast cancer. Researchers have found that inheriting two copies of a specific variant in this gene increases the risk of metastasis. Importantly, a cholesterol-lowering antibody, already approved for clinical use, appears to prevent this spread in mouse models.
Read more »
Billion-dollar bets on antibody–drug conjugatesNext-generation technology and novel targets continue to drive dealmaking around antibody–drug conjugates in oncology. Next-generation technology and novel targets continue to drive dealmaking around antibody–drug conjugates in oncology.
Read more »
Skin Autonomous Antibody Production Regulates Host-Microbiota InteractionsThis article explores the role of skin-specific immune sites in antibody production and their impact on the balance between commensal bacteria and disease-causing agents.
Read more »
The Comfort of Familiar Tropes in Unique ShowsThe article explores the prevalence of familiar tropes in new and unique television shows, arguing that this repetition offers a comforting sense of familiarity for viewers. It examines several shows, including a Japanese thriller, a Korean zombie drama, and a Brazilian science-fiction series, highlighting their similarities to popular shows like Squid Game and The Hunger Games. The author concludes that while these shows may not be entirely original, their execution and unique twists make them enjoyable experiences.
Read more »
Teva and Sanofi's Duvakitug Shows Promise in Phase 2 IBD StudyTeva Pharmaceutical and Sanofi announced positive results from a Phase 2 study of duvakitug, a monoclonal antibody, for treating ulcerative colitis (UC) and Crohn's disease (CD). The study met its primary endpoints, with duvakitug demonstrating significant clinical remission and endoscopic response rates compared to placebo. The companies plan to progress to Phase 3 trials pending regulatory approvals.
Read more »
To Combat Leukemia, Researchers Harness CD37Novel CD37 antibody-drug conjugate shows promise in targeting the Achilles’ heel of acute myeloid leukemia cells.
Read more »